https://www.selleckchem.com/
58; 95% CI 0.39-0.85, p = 0.005) and OS (HR = 0.82, 95% CI 0.70-0.96, p = 0.016), but did not significantly improve PFS (HR = 1.36; 95% CI 1.06-1.76, p = 0.017) and OS (HR = 0.98, 95% CI 0.77-1.27, p = 0.9 for MTA-containing regimens as first-line therapy in these patients. No publication bias was detected by Begg's and Egger's tests for OS and PFS. Conclusions Our results indicate that the MTA-containing therapies significantly improve OS but not for PFS in elderly mOGC patients. Sub-group analysis shows that improved efficacy is only observed in the sec
Like
Comment
Share
